• home
  • lp login
  • OVERVIEW
  • INVESTMENT STRATEGY
    • Industry Focus
    • Investment Approach
  • PROFESSIONAL TEAM
  • PORTFOLIO
  • NEWS
  • CONTACT
  • Partners
    • Bob Delaney
    • Rich DeMartini
    • Bob Hurst
    • Jeff Marcus
    • Tom Murphy
    • Barry Volpert
  • Senior Advisors
    • Count Riprand Arco-Zinneberg
    • Craig R. Callen
    • Barry Friedberg
    • Stephen Friedman
    • Kenneth B. Hamlet
    • Dr. Syaru Shirley Lin
    • Alan McCollough
    • Mackey McDonald
    • Sir Nicholas Scheele
    • Mark Sutton
  • Investment Professionals
    • Principals
      • Alex Binderow
      • Brian Cassidy
      • Quentin Chu
      • Katherine Chung
      • Adam Klein
      • Alex Rose
    • Vice Presidents
      • Cindy Cheung
      • Dan Kilpatrick
      • Caroline Nelson
    • Associates
      • Adam Barrer
      • Christine Donnelly
      • Peter Jarow
      • Jordan Katz
      • Davis Ravnaas
      • Daniel Spelman
      • Victoria Thain
      • David Victor-Smith
      • Rachel Virany
  • Finance and Operations
    • Alexandra Leonard
    • Chris Moseley
    • Ross Oliver
    • Evelyn Pellicone
    • Heather Walker

Quentin Chu

Joined Crestview in July 2005 after graduating from Harvard Business School. Prior to HBS, Mr. Chu was an associate at The Carlyle Group, where he evaluated and executed transactions in the healthcare industry, including pharmaceuticals, medical devices, facility-based providers, managed care and outsourcing. Prior to joining Carlyle, Mr. Chu was an analyst in the healthcare investment banking team at Goldman Sachs, where he completed a range of M&A and financing assignments for both early stage and Fortune 500 companies. Mr. Chu is on the board of Symbion. Mr. Chu received his A.B. in Classics from Harvard College, summa cum laude, where he was elected to Phi Beta Kappa.

Copyright 2011 Crestview Partners. All rights reserved.
Nothing contained herein constitutes an offer to sell or a solicitation of an offer to purchase any investments or securities of any investment vehicles. Any such offer or
solicitation shall be made only pursuant to a confidential offering memorandum relating to such vehicles, which will qualify in its entirety any information set forth herein.